<- Go Home
Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Market Cap
EUR 2.8B
Volume
4.5K
Cash and Equivalents
EUR 122.5M
EBITDA
EUR 277.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 976.7M
Profit Margin
66.68%
52 Week High
EUR 389.50
52 Week Low
EUR 296.00
Dividend
0.43%
Price / Book Value
2.51
Price / Earnings
18.72
Price / Tangible Book Value
5.25
Enterprise Value
EUR 3.0B
Enterprise Value / EBITDA
10.29
Operating Income
EUR 230.1M
Return on Equity
13.88%
Return on Assets
7.65
Cash and Short Term Investments
EUR 126.2M
Debt
EUR 289.6M
Equity
EUR 1.1B
Revenue
EUR 1.5B
Unlevered FCF
EUR 131.0M
Sector
Pharmaceuticals
Category
N/A